Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Ekso Bionics Holdings (EKSO) over the last 14 years, with Q3 2025 value amounting to -$2.5 million.

  • Ekso Bionics Holdings' Net Cash Flow fell 20432.25% to -$2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.6 million, marking a year-over-year decrease of 24412.31%. This contributed to the annual value of -$2.1 million for FY2024, which is 8217.99% up from last year.
  • Ekso Bionics Holdings' Net Cash Flow amounted to -$2.5 million in Q3 2025, which was down 20432.25% from -$2.9 million recorded in Q2 2025.
  • In the past 5 years, Ekso Bionics Holdings' Net Cash Flow ranged from a high of $36.7 million in Q1 2021 and a low of -$8.7 million during Q4 2022
  • In the last 5 years, Ekso Bionics Holdings' Net Cash Flow had a median value of -$2.9 million in 2025 and averaged -$531947.4.
  • Data for Ekso Bionics Holdings' Net Cash Flow shows a peak YoY increase of 168857.64% (in 2021) and a maximum YoY decrease of 29427.0% (in 2021) over the last 5 years.
  • Over the past 5 years, Ekso Bionics Holdings' Net Cash Flow (Quarter) stood at -$3.1 million in 2021, then plummeted by 182.3% to -$8.7 million in 2022, then soared by 85.26% to -$1.3 million in 2023, then tumbled by 38.23% to -$1.8 million in 2024, then crashed by 41.97% to -$2.5 million in 2025.
  • Its Net Cash Flow was -$2.5 million in Q3 2025, compared to -$2.9 million in Q2 2025 and $1.6 million in Q1 2025.